New drug combo aims to control advanced lung cancer
NCT ID NCT07381829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called HC010 combined with chemotherapy in people with advanced lung cancer that has spread or come back. The main goal is to find a safe dose and check for side effects. About 328 adults will take part, and researchers will also see if the treatment helps shrink or control tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Genetic blueprint of tumors may guide smarter cancer treatment
- New support model aims to ease burden on caregivers of older lung cancer patients
- Breath of discovery: simple test may sniff out lung cancer
- Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
- Personalized T-Cell therapy takes on advanced lung cancer